Materiality pending
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
- Enanta Pharmaceuticals reported a quarterly loss of $1.47 per share, surpassing loss estimates. - Revenues for the quarter were $17.05 million, beating expectations by 3.55%. - Company's stock has gained 61.2% year-to-date, outperforming the S&P 500. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings
- Enanta Pharmaceuticals reported a quarterly loss of $1.47 per share, surpassing loss estimates.
- Revenues for the quarter were $17.05 million, beating expectations by 3.55%.
- Company's stock has gained 61.2% year-to-date, outperforming the S&P 500.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.